PL3368579T3 - Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania - Google Patents

Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania

Info

Publication number
PL3368579T3
PL3368579T3 PL16795192T PL16795192T PL3368579T3 PL 3368579 T3 PL3368579 T3 PL 3368579T3 PL 16795192 T PL16795192 T PL 16795192T PL 16795192 T PL16795192 T PL 16795192T PL 3368579 T3 PL3368579 T3 PL 3368579T3
Authority
PL
Poland
Prior art keywords
making
methods
antibody fragments
modified antibody
hinge modified
Prior art date
Application number
PL16795192T
Other languages
English (en)
Inventor
Yu-Ju G. Meng
Hok Seon Kim
Ingrid KIM
Christoph Spiess
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3368579T3 publication Critical patent/PL3368579T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16795192T 2015-10-30 2016-10-27 Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania PL3368579T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248792P 2015-10-30 2015-10-30
US201662346905P 2016-06-07 2016-06-07
PCT/US2016/059137 WO2017075229A1 (en) 2015-10-30 2016-10-27 Hinge modified antibody fragments and methods of making
EP16795192.0A EP3368579B1 (en) 2015-10-30 2016-10-27 Hinge modified antibody fragments and methods of making

Publications (1)

Publication Number Publication Date
PL3368579T3 true PL3368579T3 (pl) 2022-03-21

Family

ID=57288500

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16795192T PL3368579T3 (pl) 2015-10-30 2016-10-27 Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania

Country Status (9)

Country Link
US (2) US10662254B2 (pl)
EP (2) EP3368579B1 (pl)
JP (3) JP6920292B2 (pl)
CN (2) CN109071674B (pl)
ES (1) ES2904553T3 (pl)
HR (1) HRP20220064T1 (pl)
PL (1) PL3368579T3 (pl)
SI (1) SI3368579T1 (pl)
WO (1) WO2017075229A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071674B (zh) * 2015-10-30 2022-08-05 豪夫迈·罗氏有限公司 铰链修饰的抗体片段和其制备方法
WO2018087349A1 (en) * 2016-11-14 2018-05-17 Morphosys Ag Fab molecules with a rodent hinge region and a non-rodent ch1 region
CN116981695A (zh) * 2022-05-06 2023-10-31 上海药明合联生物技术有限公司 含工程化铰链区的抗体及其应用
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
WO2003102157A2 (en) * 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SE0203226D0 (sv) * 2002-10-31 2002-10-31 Amersham Biosciences Ab Immunoglobulin bindning site
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP2053062A1 (en) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
PL1773885T3 (pl) * 2004-08-05 2010-09-30 Genentech Inc Humanizowani antagoniści anty c-met
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2006166905A (ja) * 2004-11-17 2006-06-29 Oita Univ 狂犬病ウイルスを効果的に中和するヒトＦａｂ抗体遺伝子群
EP2144931A2 (en) * 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
KR20080111347A (ko) * 2007-06-18 2008-12-23 이수앱지스 주식회사 암 특이적 마커에 결합하는 재조합 항체 및 그의 용도
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN102271708A (zh) * 2008-11-13 2011-12-07 新兴产品开发西雅图有限公司 Cd37免疫治疗联合疗法及其用途
WO2010122148A1 (en) * 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
US20130331297A1 (en) * 2010-07-16 2013-12-12 Avantgen, Inc. Novel peptides and uses thereof
ES2813432T3 (es) * 2011-08-17 2021-03-23 Glaxo Group Ltd Proteínas y péptidos modificados
CA2844143C (en) * 2011-08-23 2018-07-31 Roche Glycart Ag Fc-free antibodies comprising two fab fragments and methods of use
TW201444872A (zh) * 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
ES2713505T3 (es) * 2013-03-11 2019-05-22 Genzyme Corp Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno
SG11201606983SA (en) * 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CN109071674B (zh) * 2015-10-30 2022-08-05 豪夫迈·罗氏有限公司 铰链修饰的抗体片段和其制备方法

Also Published As

Publication number Publication date
JP6920292B2 (ja) 2021-08-18
JP7413322B2 (ja) 2024-01-15
EP3368579B1 (en) 2021-11-24
CN115925962A (zh) 2023-04-07
ES2904553T3 (es) 2022-04-05
JP2021181452A (ja) 2021-11-25
CN109071674B (zh) 2022-08-05
US20200308304A1 (en) 2020-10-01
JP2019504820A (ja) 2019-02-21
JP2024045138A (ja) 2024-04-02
HRP20220064T1 (hr) 2022-04-15
CN109071674A (zh) 2018-12-21
SI3368579T1 (sl) 2022-04-29
EP3368579A1 (en) 2018-09-05
US10662254B2 (en) 2020-05-26
WO2017075229A1 (en) 2017-05-04
EP4036120A1 (en) 2022-08-03
US20180305462A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
ZA202003742B (en) Anti-lag3 antibodies and antigen-binding fragments
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
HK1254953A1 (zh) 抗vista抗體和片段
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
HK1254743A1 (zh) 新穎抗密封蛋白抗體及使用方法
EP3922649C0 (en) ANTI-HTRA1 ANTIBODIES AND METHOD OF USE THEREOF
EP3313993A4 (en) ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
HK1258850A1 (zh) 抗tpbg抗體及使用方法
PL3368579T3 (pl) Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania
AU2015901092A0 (en) PAT-SM3 related antibodies and methods of making and using same